A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

Phase 1

Recruiting

• Conditions: Huntington Disease

• Registration Number: NCT06826612
• Lead Sponsor: Spark Therapeutics, Inc.

Brief Summary

The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-02-03
• Study First Submitted QC: 2025-02-10
• Study First Posted: 2025-02-14
• Study Start: 2025-02-21
• Status Verified: 2025-03
• Last Update Submitted: 2025-05-19
• Last Update Posted: 2025-05-22
• Primary Completion: 2035-01-12
• Study Completion: 2035-01-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 53

Inclusion Criteria

• Have confirmed huntingtin (HTT) cytosine-adenine-guanine (CAG) repeat length ≥40 on genetic testing and confirmation diagnostic test by the central laboratory (CL) at screening.
• Have striatal atrophy demonstrated by caudate/intracranial volume less than the age-adjusted cutoff values associated with HDISS Stage 1.
• Have UHDRS Total Motor Score (TMS) equal to or greater than the age-adjusted cutoff value associated with HDISS Stage 2.
• Have UHDRS Total Functional Capacity (TFC) greater than or equal to 11.
• Use of cholinesterase inhibitors, memantine, amantadine, or riluzole must have been at stable dosing for at least 12 weeks before screening and baseline and anticipated to remain stable during the first 12 months after SPK-10001 administration.
• Antidepressant or benzodiazepine use must have been at stable dosing for at least 12 weeks before screening and baseline and anticipated to remain stable during the first 12 months after SPK-10001 administration.
• Antipsychotics for motor symptoms or mood stabilization (i.e., irritability or aggressive behavior) and/or tetrabenazine, valbenazine, or deutetrabenazine must have been at a stable dose for at least 12 weeks before screening and baseline and are anticipated to remain stable during the first 12 months after SPK-10001 administration.

Key

Exclusion Criteria

• A safe trajectory is not able to be identified for targeting placement of the cannula into the caudate or putamen on both sides of the brain due to extent of atrophy or other anatomical features.
• Have received an antisense oligonucleotide therapy during the past year.
• History of deep brain stimulation.
• History of or intention to undergo gene therapy, cell transplantation, or brain surgery during the course of the study.
• Have participated in an investigational drug study with a systemic administration within 6 weeks or 5 half-lives of screening, whichever is longer.

Additional protocol-defined inclusion/exclusion criteria apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Primary Outcome Measures

Name	Time	Method
Number of Participants with Treatment-emergent Adverse Events (TEAEs)	Day 1 up to approximately 5 years
Severity of TEAEs	Day 1 up to approximately 5 years
Change from Baseline in Unified Huntington's Disease Rating Scale (UHDRS®) Total Functional Capacity (TFC) Score	Baseline, Month 24

Secondary Outcome Measures

Name	Time	Method
Change from Baseline in Motor Symptom Progression Based on Huntington's Disease Digital Motor Score (HDDMS)	Baseline, Months 12, 18, and 24
Change from Baseline in Composite UHDRS (cUHDRS) Score	Baseline, Months 12, 18, and 24
Change from Baseline in UHDRS TFC Score	Baseline, Months 12 and 18

Trial Locations

Locations (2)

Ohio State University; 🇺🇸 Columbus, Ohio, United States

University of Cincinnati/Cincinnati Children's Hospital; 🇺🇸 Cincinnati, Ohio, United States